SCHEMBL22917294

SCHEMBL22917294

CC(C)/C=C/c1cccc(N2CCCC2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
AGXT P21549 1/20 0.40
HDAC4 P56524 2/20 0.39
MEF2D Q14814 2/20 0.39
ABCB1 P08183 5/20 0.39
APP P05067 1/20 0.38
ADRB1 P08588 1/20 0.37
KCNQ3 O43525 1/20 0.37
KCNQ2 O43526 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22917290 0.86 CYP1A2 (0.50) ALDH1A1KDM4EMEN1KMT2AAGXT
SCHEMBL5610645 0.81 PRMT6 (0.45) PRMT6ALDH1A1KDM4EMEN1GAA
SCHEMBL28090296 0.80 PRMT6 (0.47) PRMT6ALDH1A1KDM4EMEN1GAA
SCHEMBL24784702 0.80 PTGS2 (0.54) ALDH1A1KDM4EMEN1KMT2AAPP
SCHEMBL22917289 0.78 ALDH1A1 (0.55) ALDH1A1KDM4EMEN1GAAKMT2A
SCHEMBL27840550 0.77 AGXT (0.46) PRMT6ALDH1A1KDM4EMEN1GAA
SCHEMBL27862064 0.76 PRMT6 (0.48) PRMT6ALDH1A1KDM4EMEN1GAA
SCHEMBL29377692 0.74 TRIM24 (0.60) PRMT6ALDH1A1KDM4EMEN1GAA
SCHEMBL1443579 0.74 TRIM24 (0.60) PRMT6ALDH1A1KDM4EMEN1GAA
SCHEMBL607917 0.74 ALDH1A1 (0.47) PRMT6ALDH1A1KDM4EMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220396583-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING NEUROPORE THERAPIES, INC. (US) 2022-12-15 US disclosed
US-11345713-B2 Compounds as modulators of TLR2 signaling NEUROPORE THERAPIES, INC. (US) 2022-05-31 US disclosed
US-20210024539-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING NEUROPORE THERAPIES, INC. (US) 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345713-B2 Compounds as modulators of TLR2 signaling TLR2, TLR4, TLR3 PRMT6 3796/4885ALDH1A1 4464/4885KDM4E 4623/4885
US-20220396583-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING TLR2, TLR4, TLR3 PRMT6 3796/4885ALDH1A1 4464/4885KDM4E 4623/4885
US-20210024539-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING TLR2, TLR4, TLR3 PRMT6 3796/4885ALDH1A1 4464/4885KDM4E 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.